Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes

American Heart Journal

Volumn 153, Issue 6, 2007, Pages 891-899

  Gupta, Akshay ^a   Lawrence, Andrew T ^a   Krishnan, Kousik ^a   Kavinsky, Clifford J ^a   Trohman, Richard G ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; AZITHROMYCIN; BUTYROPHENONE; CHLOROQUINE; CHLORPROMAZINE; CISAPRIDE; CLARITHROMYCIN; DISOPYRAMIDE; DOFETILIDE; DROPERIDOL; ERYTHROMYCIN; FLUCONAZOLE; HALOFANTRINE; IBUTILIDE; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; MAGNESIUM SULFATE; MESORIDAZINE; PENTAMIDINE; PHENOTHIAZINE; PROCAINAMIDE; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SOTALOL; SPARFLOXACIN; THIORIDAZINE; UNINDEXED DRUG; VORICONAZOLE;

CARDIOVASCULAR RISK; HEART ARREST; HEART VENTRICLE ARRHYTHMIA; HEMODYNAMICS; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX RATIO; STANDARDIZATION; TORSADE DES POINTES;

FEMALE; HUMANS; LONG QT SYNDROME; MALE; RISK FACTORS; TORSADES DE POINTES;

EID: 34249330240     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.01.040     Document Type: Review

References (97)

1. Selzer A., and Wray H.W. Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 30 (1964) 17-26
2. Dessertenne F. Ventricular tachycardia with 2 variable opposing foci. Arch Mal Coeur Vaiss 59 (1966) 263-272
3. Lasser K.E., Allen P.D., Woolhandler S.J., et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 287 (2002) 2215-2220
4. Sadanaga T., Sadanaga F., Yao H., et al. An evaluation of ECG leads used to assess QT prolongation. Cardiology 105 (2006) 149-154
5. Morganroth J., Brozovich F.V., McDonald J.T., et al. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 67 (1991) 774-776
6. Molnar J., Zhang F., Weiss J., et al. Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. J Am Coll Cardiol 27 (1996) 76-83
7. Vitelli L.L., Crow R.S., Shahar E., et al. Electrocardiographic findings in a healthy biracial population. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Am J Cardiol 81 (1998) 453-459
8. Sgarbossa E.B., Pinski S.L., Williams D., et al. Comparison of QT intervals in African-Americans versus Caucasians. Am J Cardiol 86 (2000) 880-882
9. Bazett H.C. An analysis of the time-relations of the electrocardiogram. Heart 7 (1920) 353-362
10. Indik J.H., Pearson E.C., Fried K., et al. Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. Heart Rhythm 3 (2006) 1003-1007
11. Surawicz B., Knilans T., and Chou T.-C. Chou's electrocardiography in clinical practice (2001), W.B. Saunders Company, Philadelphia, PA
12. Al-Khatib S.M., LaPointe N.M., and Kramer J.M. What clinicians should know about the QT interval. JAMA 289 (2003) 2120-2127
13. Spodick D.H. Reduction of QT-interval imprecision and variance by measuring the JT interval. Am J Cardiol 70 (1992) 103
14. Banker J., Dizon J., and Reiffel J. Effects of the ventricular activation sequence on the JT interval. Am J Cardiol 79 (1997) 816-819
15. Anderson M.E., Al-Khatib S.M., Roden D.M., et al. Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J 144 (2002) 769-781
16. Mitcheson J.S., Chen J., Lin M., et al. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A 97 (2000) 12329-12333
17. De Bruin M.L., Pettersson M., Meyboom R.H., et al. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 26 (2005) 590-597
18. Roden D.M., Lazzara R., Rosen M., et al. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation 94 (1996) 1996-2012
19. El-Sherif N., Craelius W., Boutjdir M., et al. Early afterdepolarizations and arrhythmogenesis. J Cardiovasc Electrophysiol 1 (1990) 145-160
20. Antzelevitch C. Role or transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes. Heart Rhythm 2 (2005) S9-S15
21. Trohman R.G., and Sahu J. Drug-induced torsade de pointes. Circulation 99 (1999) E7
22. Yap Y.G., and Camm A.J. Drug induced QT prolongation and torsades de pointes. Heart 89 (2003) 1363-1372
23. Swerdlow C.D., Martin D.J., Kass R.M., et al. The zone of vulnerability to T wave shocks in humans. J Cardiovasc Electrophysiol 8 (1997) 145-154
24. Hii J.T., Wyse D.G., Gillis A.M., et al. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation 86 (1992) 1376-1382
25. Shah R.R. Drug-induced QT dispersion: does it predict the risk of torsade de pointes?. J Electrocardiol 38 (2005) 10-18
26. Rosenbaum D.S., Jackson L.E., Smith J.M., et al. Electrical alternans and vulnerability to ventricular arrhythmias. N Engl J Med 330 (1994) 235-241
27. Zeltser D., Justo D., Halkin A., et al. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore) 82 (2003) 282-290
28. Napolitano C., Schwartz P.J., Brown A.M., et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 11 (2000) 691-696
29. Abbott G.W., Sesti F., Splawski I., et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97 (1999) 175-187
30. Makita N., Horie M., Nakamura T., et al. Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation 106 (2002) 1269-1274
31. Yang P., Kanki H., Drolet B., et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 105 (2002) 1943-1948
32. Splawski I., Timothy K.W., Tateyama M., et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 297 (2002) 1333-1336
33. Chen S., Chung M.K., Martin D., et al. SNP S1103Y in the cardiac sodium channel gene SCN5A is associated with cardiac arrhythmias and sudden death in a white family. J Med Genet 39 (2002) 913-915
34. Roden D.M. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol 21 (1998) 1029-1034
35. Zhou S., Yung Chan S., Cher Goh B., et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44 (2005) 279-304
36. Wyse K.R., Ye V., and Campbell T.J. Action potential prolongation exhibits simple dose-dependence for sotalol, but reverse dose-dependence for quinidine and disopyramide: implications for proarrhythmia due to triggered activity. J Cardiovasc Pharmacol 21 (1993) 316-322
37. Roden D.M., Woosley R.L., and Primm R.K. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 111 (1986) 1088-1093
38. Lazzara R. Antiarrhythmic drugs and torsade de pointes. Eur Heart J 14 Suppl H (1993) 88-92
39. Olshansky B., Martins J., and Hunt S. N-acetyl procainamide causing torsades de pointes. Am J Cardiol 50 (1982) 1439-1441
40. Torp-Pedersen C., Moller M., Bloch-Thomsen P.E., et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 341 (1999) 857-865
41. Kober L., Bloch P., Thomsen E., Moller M., et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet 356 (2000) 2052-2058
42. Ellenbogen K.A., Stambler B.S., Wood M.A., et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 28 (1996) 130-136
43. Stambler B.S., Wood M.A., Ellenbogen K.A., et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 94 (1996) 1613-1621
44. Hohnloser S.H., Klingenheben T., and Singh B.N. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med 121 (1994) 529-535
45. Vorperian V.R., Havighurst T.C., Miller S., et al. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 30 (1997) 791-798
46. Drouin E., Lande G., and Charpentier F. Amiodarone reduces transmural heterogeneity of repolarization in the human heart. J Am Coll Cardiol 32 (1998) 1063-1067
47. Prystowsky E.N. Effects of bepridil on cardiac electrophysiologic properties. Am J Cardiol 69 (1992) 63D-67D
48. Manouvrier J., Sagot M., Caron C., et al. Nine cases of torsade de pointes with bepridil administration. Am Heart J 111 (1986) 1005-1007
49. Pinaud D., Chabanier A., Vergnoux H., et al. Bepridil and torsades de pointes. Apropos of 11 cases. Ann Cardiol Angeiol (Paris) 36 (1987) 421-425
50. Wysowski D.K., Corken A., Gallo-Torres H., et al. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 96 (2001) 1698-1703
51. Ray W.A., Murray K.T., Meredith S., et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 351 (2004) 1089-1096
52. Lee K.L., Jim M.H., Tang S.C., et al. QT prolongation and Torsades de Pointes associated with clarithromycin. Am J Med 104 (1998) 395-396
53. Stanat S.J., Carlton C.G., Crumb W.J., et al. Characterization of the inhibitory effects of erythromycin and clarithromycin in the HERG potassium channel. Mol Cell Biochem 254 (2003) 1-7
54. Kim M.H., Berkowitz C., and Trohman R.G. Polymorphic ventricular tachycardia with a normal QT interval following azithromycin. Pacing Clin Electrophysiol 28 (2005) 1221-1222
55. Milberg P., Eckardt L., Bruns H.J., et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther 303 (2002) 218-225
56. Hagiwara T., Satoh S., Kasai Y., et al. A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia. Jpn J Pharmacol 87 (2001) 231-234
57. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 21 (2001) 1468-1472
58. Amankwa K., Krishnan S.C., and Tisdale J.E. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors. Clin Pharmacol Ther 75 (2004) 242-247
59. Eisenhauer M.D., Eliasson A.H., Taylor A.J., et al. Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients. Chest 105 (1994) 389-395
60. Kuryshev Y.A., Ficker E., Wang L., et al. Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 312 (2005) 316-323
61. Justo D., and Zeltser D. Torsade de pointes induced by systemic antifungal agents: lessons from a retrospective analysis of published case reports. Mycoses 49 (2006) 463-470
62. Nosten F., ter Kuile F.O., Luxemburger C., et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet 341 (1993) 1054-1056
63. Traebert M., Dumotier B., Meister L., et al. Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. Eur J Pharmacol 484 (2004) 41-48
64. Touze J.E., Heno P., Fourcade L., et al. The effects of antimalarial drugs on ventricular repolarization. Am J Trop Med Hyg 67 (2002) 54-60
65. Warner J.P., Barnes T.R., and Henry J.A. Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr Scand 93 (1996) 311-313
66. Su Z., Martin R., Cox B.F., et al. Mesoridazine: an open-channel blocker of human ether-a-go-go-related gene K+ channel. J Mol Cell Cardiol 36 (2004) 151-160
67. Haddad P.M., and Anderson I.M. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 62 (2002) 1649-1671
68. Glassman A.H., and Bigger J.T.J. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 158 (2001) 1774-1782
69. Krahenbuhl S., Sauter B., Kupferschmidt H., et al. Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication. Am J Med Sci 309 (1995) 315-316
70. Reilly J.G., Ayis S.A., Ferrier I.N., et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 355 (2000) 1048-1052
71. Drolet B., Vincent F., Rail J., et al. Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J Pharmacol Exp Ther 288 (1999) 1261-1268
72. Drolet B., Zhang S., Deschenes D., et al. Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. J Cardiovasc Electrophysiol 10 (1999) 1597-1604
73. Vieweg W.V., and Wood M.A. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics 45 (2004) 371-377
74. Ohnishi K., Yoshida H., Shigeno K., et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 133 (2000) 881-885
75. Barbey J.T., Pezzullo J.C., and Soignet S.L. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 21 (2003) 3609-3615
76. Drolet B., Simard C., and Roden D.M. Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation 109 (2004) 26-29
77. Ficker E., Kuryshev Y.A., Dennis A.T., et al. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 66 (2004) 33-44
78. Martell B.A., Arnsten J.H., Krantz M.J., et al. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol 95 (2005) 915-918
79. Krantz M.J., Kutinsky I.B., Robertson A.D., et al. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 23 (2003) 802-805
80. Pearson E.C., and Woosley R.L. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf 14 (2005) 747-753
81. Levine J.H., Spear J.F., Guarnieri T., et al. Cesium chloride-induced long QT syndrome: demonstration of afterdepolarizations and triggered activity in vivo. Circulation 72 (1985) 1092-1103
82. Lyon A.W., and Mayhew W.J. Cesium toxicity: a case of self-treatment by alternate therapy gone awry. Ther Drug Monit 25 (2003) 114-116
83. Pinter A., Dorian P., and Newman D. Cesium-induced torsades de pointes. N Engl J Med 346 (2002) 383-384
84. Saliba W., Erdogan O., and Niebauer M. Polymorphic ventricular tachycardia in a woman taking cesium chloride. Pacing Clin Electrophysiol 24 (2001) 515-517
85. Bocker D., and Breithardt G. Induction of arrhythmia by licorice abuse. Z Kardiol 80 (1991) 389-391
86. Eriksson J.W., Carlberg B., and Hillorn V. Life-threatening ventricular tachycardia due to liquorice-induced hypokalaemia. J Intern Med 245 (1999) 307-310
87. Miller L.G. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 158 (1998) 2200-2211
88. Chung M.K. Vitamins, supplements, herbal medicines, and arrhythmias. Cardiol Rev 12 (2004) 73-84
89. Fenichel R.R., Malik M., Antzelevitch C., et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 15 (2004) 475-495
90. Marcus F.I. Risks of initiating therapy with sotalol for treatment of atrial fibrillation. J Am Coll Cardiol 32 (1998) 177-180
91. Chung M.K., Schweikert R.A., Wilkoff B.L., et al. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. J Am Coll Cardiol 32 (1998) 169-176
92. Banai S., and Tzivoni D. Drug therapy for torsade de pointes. J Cardiovasc Electrophysiol 4 (1993) 206-210
93. Khan I.A. Clinical and therapeutic aspects of congenital and acquired long QT syndrome. Am J Med 112 (2002) 58-66
94. Pinski S.L., Eguia L.E., and Trohman R.G. What is the minimal pacing rate that prevents torsades de pointes? Insights from patients with permanent pacemakers. Pacing Clin Electrophysiol 25 (2002) 1612-1615
95. Trohman R.G., Kim M.H., and Pinski S.L. Cardiac pacing: the state of the art. Lancet 364 (2004) 1701-1719
96. Viskin S. Torsades de pointes. Curr Treat Options Cardiovasc Med 1 (1999) 187-195
97. Viskin S. Cardiac pacing in the long QT syndrome: review of available data and practical recommendations. J Cardiovasc Electrophysiol 11 (2000) 593-600